India’s top-ranked drug firm, Sun Pharmaceutical Industries Ltd., reported a decline in earnings for the fourth quarter ended March 2017 dented, in part, by the challenging generic pricing environment in the US and management commentary indicates a tough fiscal 2018 ahead.
Fourth quarter sales declined by 8% to INR68.25bn ($1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?